Baby dies a day after administration of pentavalent vaccination, claim parents

NP NEWS 24 ONLINE- A three-and-half-year-old infant died a day after being administered by pentavalent vaccination.

This incident took place in Kathauli village, Pandharpur. This three-and-half-year-old was given a pentavalent vaccination a day ago after the bay died such has been alleged by the parents of the child.

The vaccine was injected by Anganwadi medical team on Tuesday and on Wednesday morning died. The name of the deceased baby’s father is Dattatray Athakle. The parents alleged the doctors of their carelessness and have claimed this incident to be utmost negligence of the doctors in the medical team.

This incident in which a three-and-half-year-old lost its life has created chaos in the area and people have become tense.

Earlier, in an incident which took place in Kerala during the month of March, four children died after they were administered a pentavalent vaccination.

And after that, in the month of April this year, a two-and-half-year-old baby died in Karnataka after was given pentavalent vaccination which was the fourth case of death which took place in the state due to the administration of pentavalent vaccination.

The matter is seriously been looked into as the main reason of the baby’s death is yet to be determined!

What is a Pentavalent vaccination?

Pentavalent vaccination is a five-in-one vaccine under national immunization programme headed by Indian Council of Medical Research(ICMR).

The diseases which were covered by the five-in-one vaccine are Diptheria, Tetanus, Pertussis(whooping cough), Hepatitis B and Haemophilus Influnzae Type B which can cause severe type of Pneumonia and Meningitis.

In September 2006, the first Pentavalent vaccine formulation received pre-qualification approval from the World Health Organization(WHO).

The major companies which have introduced the vaccination in the domestic market are Sanofi-aventis, Shantha Biotech, Serum Institue of India,  Bharat Biotech and Panacea Biotec.

Comments are closed.